ABX300

ABX300 is an experimental **small-molecule** obesity drug reported to target the splicing factor **serine and arginine rich splicing factor 1** and to modulate **LMNA** alternative splicing. In the provided preclinical description, the compound binds the RS domain of SRSF1 and reversed diet-induced obesity phenotypes in mice, with restoration of adipose tissue homeostasis, increased oxygen consumption, and a shift toward lipid utilization, while showing no effect in chow-fed animals. Based on the supplied information, ABX300 appears to be a preclinical RNA-splicing modulator being explored for **obesity** treatment; no confirmed brand name, manufacturer, dosage form, route, or late-stage clinical development details were identified from the provided context.